Allogeneic cell therapy hasn’t caught up to autologous cell therapy yet, and the disappointing data so far has soured the entire allogeneic field for at least one venture capitalist. The cell therapy debate was one of the topics covered during a panel discussion at the Biopharm America conference.
The final day of the conference, Friday, December 11, includes a panel on precision medicine investment trends, a look at clinical trial design innovation and the life sciences track of our Pitch Perfect startup contest. Register now!
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Parexel, one of the largest CROs in the world, said the partnership would involve connecting real-world data across the clinical trials it conducts.
Experts at last week's BIO meeting in Philadelphia discussed the long-term implications of many gene therapies hitting the market, and ways their prices could be lowered so they'd be more cost-effective.
The report, by CRO Worldwide Clinical Trials, shows growing need for early-stage development expertise, with high demand for data quality, efficiency and overall trial management.
Growth in the CRO sector is expected to accompany growth of clinical trials, their complexity and regulatory requirements.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.